Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Stroke. 2014 Nov 25;46(1):229–236. doi: 10.1161/STROKEAHA.114.006982

Figure 5. Chronic topiramate and lamotrigine treatment improves stroke outcomes in FHM1 mutant mice.

Figure 5

A) Whisker-box plot summarizes the indirect infarct volumes after 7 weeks of daily treatment with vehicle (VEH, blue), topiramate (TPM, red) or lamotrigine (LTG, green) in R192Q mutant mice. Neurological deficit scores are also shown in individual animals. n=7, 10 and 10 mice in vehicle, topiramate and lamotrigine groups, respectively. *p<0.05 vs. vehicle. One-way ANOVA followed by Holm-Sidak's multiple comparisons test for infarct volume, and Kruskal-Wallis followed by Dunn's multiple comparisons test for neurological deficit score. Infarct volume: treatment effect F(2,24)=6.0, p=0.0075. Neuroscore: treatment effect Kruskal-Wallis statistic 8.6, p=0.0136. Post-hoc comparisons: *p<0.05 vs. vehicle.

B) Whisker-box plot summarizes AD latency after a single dose of vehicle, topiramate or lamotrigine (LTG, green) in R192Q mutant mice. n=5, 11 and 10 mice in vehicle, topiramate and lamotrigine groups, respectively. One-way ANOVA followed by Holm-Sidak's multiple comparisons test. Treatment effect F(2,23)=6.8, p=0.0048. Post-hoc comparisons: *p<0.05 vs. vehicle and topiramate.